Dasabuvir is a potent direct-acting antiviral medication classified as a non-nucleoside NS5B polymerase inhibitor, used in combination therapy to treat chronic hepatitis C virus (HCV) infection. This category… Read more









Dasabuvir is a potent direct-acting antiviral medication classified as a non-nucleoside NS5B polymerase inhibitor, used in combination therapy to treat chronic hepatitis C virus (HCV) infection. This category provides access to high-quality reference standards for dasabuvir, including its relevant degradation products and synthetic intermediates, such as O-desmethyl dasabuvir and N-nitroso dasabuvir. These compounds are essential for rigorous impurity profiling and method validation, ensuring compliance with pharmaceutical quality control standards. Laboratories also utilize stable isotope-labelled compounds, such as dasabuvir-d9 and dasabuvir-13C-d3, as internal standards in liquid chromatography-mass spectrometry (LC-MS) to enhance the precision of pharmacokinetic studies and quantification assays. By incorporating these analytical tools, researchers can effectively monitor drug stability and ensure the accuracy of analytical results throughout the drug development lifecycle.